NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Here is response from AI:

“
What IFRs are: Applications by clinicians to fund NHS treatments for approved medicines or procedures that are not routinely commissioned or reimbursed by local Integrated Care Boards (ICBs) or NHS England.
Approval criteria: IFRs are approved only when patients demonstrate “clinical exceptionality,” meaning:
• The patient is significantly different from others with the same condition
• The patient is likely to gain significantly more benefit from the treatment than typical patients
• Clinical effectiveness and cost-effectiveness are demonstrated
Why statistics may not be public:
• Different ICBs handle their own IFR processes with varying criteria
• No centralized national reporting system appears to exist
• Approval rates likely vary significantly by region, condition, and treatment type
The high bar for approval: The process descriptions suggest approval rates may be relatively low, given the strict requirement for “exceptionality” and the fact that treatments must come from existing budgets. However, without published data, I cannot provide a specific percentage.
If you need this information for a specific purpose, you might consider contacting individual ICBs directly or submitting Freedom of Information requests to NHS England or specific ICBs for their approval/decline statistics”